Korsching Eberhard, Packeisen Jens, Liedtke Cornelia, Hungermann Daniela, Wülfing Pia, van Diest Paul J, Brandt Burkhard, Boecker Werner, Buerger Horst
Institute of Pathology, University of Münster, Germany.
J Pathol. 2005 Aug;206(4):451-7. doi: 10.1002/path.1797.
Vimentin expression is a rather rare finding in invasive breast cancer, and is associated with high tumour invasiveness and chemoresistance. It is currently explained by two different biological theories: direct histogenetic derivation from myoepithelial cells, and epithelial-mesenchymal transition (EMT) reflecting the end-stage of breast cancer dedifferentiation. In this study we aimed to obtain further insights into the biological hallmarks of these vimentin-expressing breast cancers. We applied immunohistochemistry for vimentin and 15 other differentiation markers to a series of 364 invasive breast cancer cases, using tissue microarray technology. 7.7% of all tumours expressed vimentin. Almost all of these cases (19/21) were Grade 3 invasive ductal carcinomas, and the majority (13/21) of these were associated with a ductal in situ component. Vimentin expression was also seen in the respective in situ components and correlated positively with the expression of SMA, CD10, CK 5, p53, Mib-1 and EGFR. A negative correlation was seen for the expression of CK 8/18 and the oestrogen receptor. Vimentin-expressing carcinomas revealed a significantly higher average absolute number of cytogenetic alterations per case, but a significantly lower frequency of chromosome 16q losses compared to vimentin-negative cases. Our present results demonstrate that, despite analogies between vimentin-positive breast cancers and myoepithelial cells in their expression of differentiation-related proteins, neither myoepithelial histogenesis nor EMT can exclusively explain the biology of these distinct tumours. This is mainly supported by the significantly higher incidence of vimentin-expressing breast cancers compared to any other myoepithelial breast tumours and the fact that vimentin is already observed in ductal in situ components. We therefore propose the alternative hypothesis that vimentin-expressing breast carcinomas may derive from breast progenitor cells with bilinear (glandular and myoepithelial) differentiation potential.
波形蛋白表达在浸润性乳腺癌中较为罕见,且与肿瘤的高侵袭性和化疗耐药性相关。目前有两种不同的生物学理论对此进行解释:一是直接起源于肌上皮细胞的组织发生,二是上皮-间质转化(EMT),反映了乳腺癌去分化的终末期。在本研究中,我们旨在进一步深入了解这些波形蛋白表达阳性的乳腺癌的生物学特征。我们运用组织芯片技术,对364例浸润性乳腺癌病例进行了波形蛋白及其他15种分化标志物的免疫组化检测。所有肿瘤中7.7%表达波形蛋白。几乎所有这些病例(21例中的19例)为3级浸润性导管癌,其中大多数(21例中的13例)与导管原位成分相关。波形蛋白表达也见于各自的原位成分中,并与平滑肌肌动蛋白(SMA)、CD10、细胞角蛋白5(CK 5)、p53、增殖细胞核抗原(Mib-1)和表皮生长因子受体(EGFR)的表达呈正相关。细胞角蛋白8/18(CK 8/18)和雌激素受体的表达呈负相关。与波形蛋白阴性的病例相比,波形蛋白表达阳性的癌显示出每例细胞遗传学改变的平均绝对数量显著更高,但16号染色体q臂缺失的频率显著更低。我们目前的结果表明,尽管波形蛋白阳性乳腺癌与肌上皮细胞在分化相关蛋白表达方面存在相似之处,但肌上皮组织发生和EMT都不能完全解释这些独特肿瘤的生物学特性。这主要得到以下两点支持:与任何其他肌上皮性乳腺肿瘤相比,波形蛋白表达阳性的乳腺癌发病率显著更高;以及在导管原位成分中已观察到波形蛋白这一事实。因此,我们提出另一种假设,即波形蛋白表达阳性的乳腺癌可能起源于具有双系(腺性和肌上皮)分化潜能的乳腺祖细胞。